Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Ruff CT, et al. Among authors: salazar d. Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042. Am Heart J. 2010. PMID: 20934556 Clinical Trial.
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Weitz JI, et al. Among authors: salazar d. Thromb Haemost. 2010 Sep;104(3):633-41. doi: 10.1160/TH10-01-0066. Epub 2010 Aug 5. Thromb Haemost. 2010. PMID: 20694273 Clinical Trial.
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L. Wrishko RE, et al. Among authors: salazar de. J Clin Pharmacol. 2009 Aug;49(8):984-98. doi: 10.1177/0091270009337942. Epub 2009 Jun 22. J Clin Pharmacol. 2009. PMID: 19546250
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, Farid NA, Ni L, Jakubowski JA, Salazar DE, Thieu VT, Payne CD. Small DS, et al. Among authors: salazar de. Eur J Clin Pharmacol. 2010 Feb;66(2):127-35. doi: 10.1007/s00228-009-0737-1. Epub 2009 Nov 4. Eur J Clin Pharmacol. 2010. PMID: 19888568 Clinical Trial.
365 results